JP2019515676A5 - - Google Patents

Download PDF

Info

Publication number
JP2019515676A5
JP2019515676A5 JP2018555460A JP2018555460A JP2019515676A5 JP 2019515676 A5 JP2019515676 A5 JP 2019515676A5 JP 2018555460 A JP2018555460 A JP 2018555460A JP 2018555460 A JP2018555460 A JP 2018555460A JP 2019515676 A5 JP2019515676 A5 JP 2019515676A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
sequence
acid sequence
alk7
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018555460A
Other languages
English (en)
Japanese (ja)
Other versions
JP7103950B2 (ja
JP2019515676A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/028952 external-priority patent/WO2017185037A1/en
Publication of JP2019515676A publication Critical patent/JP2019515676A/ja
Publication of JP2019515676A5 publication Critical patent/JP2019515676A5/ja
Application granted granted Critical
Publication of JP7103950B2 publication Critical patent/JP7103950B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018555460A 2016-04-22 2017-04-21 Alk7結合性タンパク質及びその使用 Active JP7103950B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662326313P 2016-04-22 2016-04-22
US62/326,313 2016-04-22
PCT/US2017/028952 WO2017185037A1 (en) 2016-04-22 2017-04-21 Alk7 binding proteins and uses thereof

Publications (3)

Publication Number Publication Date
JP2019515676A JP2019515676A (ja) 2019-06-13
JP2019515676A5 true JP2019515676A5 (enExample) 2020-06-11
JP7103950B2 JP7103950B2 (ja) 2022-07-20

Family

ID=60089402

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018555460A Active JP7103950B2 (ja) 2016-04-22 2017-04-21 Alk7結合性タンパク質及びその使用

Country Status (8)

Country Link
US (4) US10501547B2 (enExample)
EP (1) EP3445394A4 (enExample)
JP (1) JP7103950B2 (enExample)
KR (2) KR102405278B1 (enExample)
CN (3) CN116217731B (enExample)
AU (1) AU2017252574B2 (enExample)
CA (1) CA3018272A1 (enExample)
WO (1) WO2017185037A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3413912A4 (en) 2016-02-11 2019-09-25 The Johns Hopkins University COMPOSITIONS AND METHODS FOR TARGETING ACTIVIN SIGNALING FOR THE TREATMENT OF CANCER
CN116217731B (zh) 2016-04-22 2025-12-30 艾科赛扬制药股份有限公司 Alk7结合蛋白及其用途
EP3694545A4 (en) 2017-10-11 2021-12-01 Board Of Regents, The University Of Texas System HUMAN PD-L1 ANTIBODIES AND METHOD OF USING THEM
BR112020007751A2 (pt) * 2017-10-25 2020-10-20 Acceleron Pharma Inc. proteínas de ligação de alk7 e usos das mesmas
WO2019182867A1 (en) 2018-03-23 2019-09-26 Board Of Regents, The University Of Texas System Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
CA3092695A1 (en) 2018-03-23 2019-09-26 Board Of Regents, The University Of Texas System Human pd-l2 antibodies and methods of use therefor
US12187799B2 (en) 2018-03-23 2025-01-07 Board Of Regents, The University Of Texas System Dual specificity antibodies to PD-L1 and PD-L2 and methods of use therefor
CA3142147A1 (en) * 2019-05-30 2020-12-03 Acceleron Pharma Inc. Alk7 binding proteins and uses thereof
EP4217378A4 (en) * 2020-10-08 2025-02-26 The Trustees Of Dartmouth College Methods and agents for treating, preventing, diagnosing, and evaluating therapy for fibrotic, autoimmune, and inflammatory conditions

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3546807C2 (enExample) 1985-03-30 1991-03-28 Marc Genf/Geneve Ch Ballivet
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0478627A4 (en) 1989-05-16 1992-08-19 William D. Huse Co-expression of heteromeric receptors
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5614609A (en) * 1994-10-20 1997-03-25 Carlos F. Ibanez Serine threonine kinase receptor
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6696248B1 (en) 1995-08-18 2004-02-24 Morphosys Ag Protein/(poly)peptide libraries
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
WO1997011971A1 (en) 1995-09-28 1997-04-03 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
EP0990034A1 (de) * 1997-06-06 2000-04-05 Asat AG Applied Science & Technology Anti-gpiib/iiia rekombinante antikörper
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ,インコーポレイティド 人工抗体ポリペプチド
ATE482275T1 (de) 1999-07-02 2010-10-15 Morphosys Ag Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
ATE486842T1 (de) 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
HUE026914T2 (en) 2002-11-07 2016-08-29 Immunogen Inc Anti-CD33 antibodies and a method of treating acute myeloid leukemia
AU2004252109B2 (en) 2003-06-11 2010-04-08 Merck Sharp & Dohme Corp. Substituted 3-alkyl and 3-alkenyl azetidine derivatives
WO2005075514A2 (en) 2004-03-10 2005-08-18 Lonza Ltd. Method for producing antibodies
AU2005279347A1 (en) 2004-08-30 2006-03-09 Lonza Biologics Plc. Affinity- plus ion exchange- chromatography for purifying antibodies
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
PL2860192T3 (pl) 2005-10-12 2018-03-30 Morphosys Ag Wytwarzanie i profilowanie w pełni ludzkich, uzyskanych z HuCAL GOLD terapeutycznych przeciwciał swoistych wobec ludzkiego CD38
ES2965283T3 (es) 2006-03-15 2024-05-28 Alexion Pharma Inc Tratamiento de pacientes con hemoglobinuria paroxística nocturna mediante un inhibidor del complemento
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
US20090155275A1 (en) 2007-07-31 2009-06-18 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8093364B2 (en) 2008-01-18 2012-01-10 Bio-Rad Laboratories, Inc. Enhanced purification of antibodies and antibody fragments by apatite chromatography
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
EP2376534A4 (en) * 2008-12-05 2012-05-30 Abraxis Bioscience Llc SPARC-BINDING ScFc
JP5912078B2 (ja) * 2009-06-08 2016-04-27 アクセルロン ファーマ, インコーポレイテッド 熱発生性脂肪細胞を増加させるための方法
KR102024922B1 (ko) 2010-07-16 2019-09-25 아디맵 엘엘씨 항체 라이브러리
CN104936980B (zh) * 2012-12-31 2019-06-07 生物控股有限公司 用于治疗和预防多瘤病毒相关的疾病的重组人抗体
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
WO2014179363A1 (en) 2013-04-29 2014-11-06 Adimab, Llc Polyspecificity reagents, methods for their preparation and use
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
WO2015091935A2 (en) * 2013-12-19 2015-06-25 Arsanis Biosciences Gmbh Antibodies directed against the lukgh (lukab) toxin of staphylococcus aureus and antibody sequences
KR101644043B1 (ko) 2014-03-18 2016-08-01 한국과학기술원 Rna에 특이적으로 결합하는 항체
EP3439741B1 (en) 2016-04-06 2026-05-20 Acceleron Pharma Inc ACTRIIB:ALK7 HETEROMULTIMERS FOR THERAPEUTIC BODY WEIGHT REDUCTION
CN116217731B (zh) 2016-04-22 2025-12-30 艾科赛扬制药股份有限公司 Alk7结合蛋白及其用途
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor
BR112020007751A2 (pt) 2017-10-25 2020-10-20 Acceleron Pharma Inc. proteínas de ligação de alk7 e usos das mesmas

Similar Documents

Publication Publication Date Title
JP2024026159A5 (enExample)
JP2021527714A (ja) 抗pd−1抗体及びその使用
CN109311971A (zh) 抗TL1A/抗TNF-α双特异性抗原结合蛋白及其用途
JP7103950B2 (ja) Alk7結合性タンパク質及びその使用
JP2010043089A5 (enExample)
AU2010229705A1 (en) Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
JP2019513015A5 (enExample)
JP2022534966A5 (enExample)
WO2013147212A1 (ja) 新規抗Siglec-15抗体
JP2013503626A (ja) グルカゴン受容体に対する抗体と、それらの使用
WO2013147213A1 (ja) CDR改変抗Siglec-15抗体
JP2021500895A5 (enExample)
IL295979A (en) Anti-cd36 antibodies and their use for cancer treatment
CA3192208A1 (en) Anti-par-2 antibodies and methods of use thereof
JP7698635B2 (ja) 抗幹細胞因子抗体及びその使用方法
WO2017088782A1 (zh) 抗pcsk9抗体及其应用
KR20200096223A (ko) Ildr2 길항제 및 그의 조합물
JP2022534514A5 (enExample)
JP7617036B2 (ja) Alk7結合タンパク質及びその使用
JP7510208B2 (ja) 抗TrkA抗体又はその抗原結合フラグメント、その調製方法及び使用
TW201012476A (en) Induction of p53 expression by neutralization of neuropilin-2 for the treatment of cancers
RU2652880C2 (ru) Антитело против рецептора эпидермального фактора роста
JP2024505987A (ja) 抗tnfr2抗体およびその使用
JP7756686B2 (ja) ネコMcDonough肉腫(FMS)様チロシンキナーゼ3受容体リガンド(FLT3L)に対する抗体並びに自己免疫疾患及び炎症性疾患を治療するためのそれらの使用
WO2021058735A1 (en) Cancer treatment with anti-met antibody compositions